Amyloidosis is an underdiagnosed, progressive group of diseases characterized by the abnormal buildup of a protein called ...

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

Localized amyloidosis is usually less serious than the systemic form. Diagnosis is also complicated by the fact that the symptoms of amyloidosis are similar to those seen in other conditions that ...

Treatment options have also been limited — Lousada, now CEO of the nonprofit Amyloidosis Research Consortium in Newton, Massachusetts, was fortunate to survive thanks to a stem cell transplant that is ...

Amyloidosis, a disease in which misfolded proteins form amyloid fibrils that deposit in tissues and organs including the heart, is a vexing condition with devastating consequences. Encouragingly ...

PITTSBURGH (KDKA) -- Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really didn't think ...

Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the ...

Treatment of primary or AL amyloidosis The treatments used in primary amyloidosis are the same as those used to treat multiple myeloma and include chemotherapy, corticosteroids and proteosome ...